Company family
Auro: medicine shortages
As of 2 Nov 2026, 21 Auro products have a reported shortage across 1 countries, covering 12 medicines.
Products short21rank #103 of 464
Medicines12active ingredients
Countries1/16
New in 90 days2-2 vs market pace
Typical duration2.2 yearsmedian so far
Manufacturing55%demand-driven 40%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Long-run trend in Canada
Canada dashboardCanada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Valsartan and Diuretics | 5 | 26 Aug 2024 | Increased demand | 7/16 | |
| Irbesartan | 3 | 17 Oct 2018 | Manufacturing problem | 6/16 | |
| Irbesartan and Diuretics | 3 | 17 Sep 2018 | Manufacturing problem | 4/16 | |
| Perindopril | 2 | 9 Jun 2026 | Manufacturing problem | 5/16 | |
| Candesartan and Diuretics | 1 | 18 Jun 2026 | Manufacturing problem | 5/16 | |
| Cefalexin | 1 | 12 Feb 2024 | Increased demand | 3/16 | |
| Febuxostat | 1 | 26 Aug 2024 | Increased demand | 6/16 | |
| Risedronic Acid | 1 | 5 Mar 2019 | Manufacturing problem | 3/16 | |
| Ritonavir | 1 | 26 Oct 2026 | Other | 6/16 | |
| Rizatriptan | 1 | 1 Aug 2018 | Manufacturing problem | 6/16 | |
| Valganciclovir | 1 | 3 Oct 2025 | Manufacturing problem | 5/16 | |
| Zidovudine and Lamivudine | 1 | not given | Not stated | 1/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.